Cerus Europe B.V.
Stationsstraat 79-D
3811MH Amersfoort
NetherlandsCerus Corporation is a biomedical products company focused in the field of blood safety. The INTERCEPT™ Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens like viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate transfusion threats, like hepatitis B and C,HIV,West Nile virus, Chikungunya, malaria, dengue and bacteria.Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in USA,Europe,CIS, the Middle East and selected countries in other regions around the world.
